Abstract:Immune checkpoint inhibitors targeting programmed cell death protein 1, programmed death-ligand 1, and cytotoxic T-lymphocyte-associated protein 4 provide deep and durable treatment responses which have revolutionized oncology. However, despite over 40% of cancer patients being eligible to receive immunotherapy, only 12% of patients gain benefit. A key to understanding what differentiates treatment response from non-response is better defining the role of the innate immune system in anti-tumor immunity and immune tolerance. Teleologically, myeloid cells, including macrophages, dendritic cells, monocytes, and neutrophils, initiate a response to invading pathogens and tissue repair after pathogen clearance is successfully accomplished. However, in the tumor microenvironment (TME), these innate cells are hijacked by the tumor cells and are imprinted to furthering tumor propagation and dissemination. Major advancements have been made in the field, especially related to the heterogeneity of myeloid cells and their function in the TME at the single cell level, a topic that has been highlighted by several recent international meetings including the 2021 China Cancer Immunotherapy workshop in Beijing. Here, we provide an up-to-date summary of the mechanisms by which major myeloid cells in the TME facilitate immunosuppression, enable tumor growth, foster tumor plasticity, and confer therapeutic resistance. We discuss ongoing strategies targeting the myeloid compartment in the preclinical and clinical settings which include: (1) altering myeloid cell composition within the TME; (2) functional blockade of immune-suppressive myeloid cells; (3) reprogramming myeloid cells to acquire pro-inflammatory properties; (4) modulating myeloid cells via cytokines; (5) myeloid cell therapies; and (6) emerging targets such as Siglec-15, TREM2, MARCO, LILRB2, and CLEVER-1. There is a significant promise that myeloid cell-based immunotherapy will help advance immuno-oncology in years to come.

Biophysical heterogeneity of myeloid-derived microenvironment to regulate resistance to cancer immunotherapy

Suppressive Myeloid Cells Shape the Tumor Immune Microenvironment

Decoding the spatiotemporal heterogeneity of tumor-associated macrophages

Heterogeneity of myeloid cells in common cancers: Single cell insights and targeting strategies

Heterogeneity of the tumor immune microenvironment and its clinical relevance

Macrophage heterogeneity and its interactions with stromal cells in tumour microenvironment

Tumor-associated myeloid cells in cancer immunotherapy

Unravelling Tumour Microenvironment in Melanoma at Single-Cell Level and Challenges to Checkpoint Immunotherapy

Heterogeneous Myeloid Cells in Tumors

Emerging strategies in targeting tumor-resident myeloid cells for cancer immunotherapy

Targeting the tumor biophysical microenvironment to reduce resistance to immunotherapy

Immunotherapy Targeting Myeloid-Derived Suppressor Cells (MDSCs) in Tumor Microenvironment

Tumor Microenvironment Heterogeneity, Potential Therapeutic Avenues, and Emerging Therapies

Redefining Tumor-Associated Macrophage Subpopulations and Functions in the Tumor Microenvironment

Tumor-associated macrophages, dendritic cells, and neutrophils: biological roles, crosstalk, and therapeutic relevance

Aspects of the Tumor Microenvironment Involved in Immune Resistance and Drug Resistance

Roles of immune microenvironment heterogeneity in therapy-associated biomarkers in lung cancer.

Macrophage barrier in the tumor microenvironment and potential clinical applications

The heterogeneity of tumour-associated macrophages contributes to the clinical outcomes and indications for immune checkpoint blockade in colorectal cancer patients

Single-Cell Informatics for Tumor Microenvironment and Immunotherapy

Biomaterials tools to modulate the tumour microenvironment in immunotherapy